These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 19903356)
1. Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro. Dupart JJ; Trent JC; Lee HY; Hess KR; Godwin AK; Taguchi T; Zhang W Mol Cancer; 2009 Nov; 8():99. PubMed ID: 19903356 [TBL] [Abstract][Full Text] [Related]
2. Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor. Trent JC; Ramdas L; Dupart J; Hunt K; Macapinlac H; Taylor E; Hu L; Salvado A; Abbruzzese JL; Pollock R; Benjamin RS; Zhang W Cancer; 2006 Oct; 107(8):1898-908. PubMed ID: 16986125 [TBL] [Abstract][Full Text] [Related]
3. Augmentation of multiple protein kinase activities associated with secondary imatinib resistance in gastrointestinal stromal tumors as revealed by quantitative phosphoproteome analysis. Nagata K; Kawakami T; Kurata Y; Kimura Y; Suzuki Y; Nagata T; Sakuma Y; Miyagi Y; Hirano H J Proteomics; 2015 Feb; 115():132-42. PubMed ID: 25554490 [TBL] [Abstract][Full Text] [Related]
4. Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells. Reynoso D; Nolden LK; Yang D; Dumont SN; Conley AP; Dumont AG; Zhou K; Duensing A; Trent JC Mol Oncol; 2011 Feb; 5(1):93-104. PubMed ID: 21115411 [TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Tarn C; Rink L; Merkel E; Flieder D; Pathak H; Koumbi D; Testa JR; Eisenberg B; von Mehren M; Godwin AK Proc Natl Acad Sci U S A; 2008 Jun; 105(24):8387-92. PubMed ID: 18550829 [TBL] [Abstract][Full Text] [Related]
6. microRNA-218 increase the sensitivity of gastrointestinal stromal tumor to imatinib through PI3K/AKT pathway. Fan R; Zhong J; Zheng S; Wang Z; Xu Y; Li S; Zhou J; Yuan F Clin Exp Med; 2015 May; 15(2):137-44. PubMed ID: 24706111 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors. Cohen NA; Zeng S; Seifert AM; Kim TS; Sorenson EC; Greer JB; Beckman MJ; Santamaria-Barria JA; Crawley MH; Green BL; Rossi F; Besmer P; Antonescu CR; DeMatteo RP Cancer Res; 2015 May; 75(10):2061-70. PubMed ID: 25836719 [TBL] [Abstract][Full Text] [Related]
8. Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor. Pessetto ZY; Ma Y; Hirst JJ; von Mehren M; Weir SJ; Godwin AK Mol Cancer Ther; 2014 Oct; 13(10):2276-87. PubMed ID: 25122069 [TBL] [Abstract][Full Text] [Related]
9. microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Akçakaya P; Caramuta S; Åhlen J; Ghaderi M; Berglund E; Östman A; Bränström R; Larsson C; Lui WO Br J Cancer; 2014 Nov; 111(11):2091-102. PubMed ID: 25349971 [TBL] [Abstract][Full Text] [Related]
10. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate. Liu Y; Tseng M; Perdreau SA; Rossi F; Antonescu C; Besmer P; Fletcher JA; Duensing S; Duensing A Cancer Res; 2007 Mar; 67(6):2685-92. PubMed ID: 17363589 [TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Croom KF; Perry CM Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228 [TBL] [Abstract][Full Text] [Related]
12. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Bauer S; Duensing A; Demetri GD; Fletcher JA Oncogene; 2007 Nov; 26(54):7560-8. PubMed ID: 17546049 [TBL] [Abstract][Full Text] [Related]
13. [Establishment and pathologic analysis of imatinib-resistant gastrointestinal stromal tumor xenografts]. Zheng S; Wang XJ; Jia J; Pan YL; Tao DY; Lu HS; Huang KE Zhonghua Bing Li Xue Za Zhi; 2012 Mar; 41(3):176-80. PubMed ID: 22800481 [TBL] [Abstract][Full Text] [Related]
14. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines. Noma K; Naomoto Y; Gunduz M; Matsuoka J; Yamatsuji T; Shirakawa Y; Nobuhisa T; Okawa T; Takaoka M; Tomono Y; Hiroyuki O; Gunduz E; Tanaka N Oncol Rep; 2005 Sep; 14(3):645-50. PubMed ID: 16077968 [TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate induces quiescence in gastrointestinal stromal tumor cells through the CDH1-SKP2-p27Kip1 signaling axis. Liu Y; Perdreau SA; Chatterjee P; Wang L; Kuan SF; Duensing A Cancer Res; 2008 Nov; 68(21):9015-23. PubMed ID: 18974147 [TBL] [Abstract][Full Text] [Related]